Labcorp's expertise in inhalation toxicology and end-to-end early phase development solutions (EPDS) enabled a leading Japanese pharmaceutical company to fast-track the global development of a novel inhaled large-molecule drug. With plans to commercialize in various geographies across the world, the company needed a lab partner with specialized inhalation capabilities and global reach. Labcorp's extensive inhalation toxicology expertise, including experience with non-human primate models, positioned them as the ideal testing partner. Their EPDS team provided customized guidance and seamless coordination to accelerate the program. Through high-touch partnership and local representatives, Labcorp delivered tailored support that met the client's specific needs and challenges. This case study illustrates how Labcorp helped their client capitalize on the growing inhaled drug market and advance an important new therapy globally.

• Download